Product
Ulonivirine
Aliases
MK-8507, Placebo to Ulonivirine
3 clinical trials
2 indications
Indication
HIV-1 InfectionIndication
Liver InsufficiencyClinical trial
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-DailyStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
An Open-Label, Single-Dose Clinical Study to Evaluate Pharmacokinetics of MK-8507 in Participants With Mild or Moderate Hepatic Impairment.Status: Not yet recruiting, Estimated PCD: 2025-04-03
Clinical trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-8507 in HIV-1 Infected PatientsStatus: Completed, Estimated PCD: 2015-07-16